PURPOSE: Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and cancer progression. The VEGF genetic polymorphisms were shown to be independently associated with an adverse outcome in various malignancies. We investigated the possible associations of two polymorphisms (-2578C/A and +936C/T) in the VEGF gene with the clinicopathologic parameters for patients with non-Hodgkin's lymphoma (NHL). METHODS: We studied the genotype and allele frequencies of the -2578C/A and +936C/T polymorphism in DNA samples of 431 patients with NHL using restriction fragment length polymorphism typing analysis. RESULTS: The -2578A allele was significantly associated with less frequent clinical staging III, IV and bone marrow involvement (The odds ratio (OR) 0.59; 95% confidence interval (CI) 0.43-0.82; and OR 0.66; 95% CI 0.48-0.91, respectively). The CA and CA + AA genotype of the -2578C/A were significantly associated with less frequent bone marrow involvement than CC genotypes (OR 0.57; 95% CI 0.38-0.86; and OR 0.57; 95% CI 0.39-0.85, respectively). The TT genotype of the +936C/T polymorphism was significantly associated with less frequent T cell histological type, clinical staging III, IV and bone marrow involvement (OR 0.25; 95% CI 0.07-0.89; OR 0.37; 95% CI 0.15-0.89; and OR 0.31; 95% CI 0.10-0.96, respectively). The +936 T allele was marginally associated with less frequent bone marrow involvement and with Clinical staging III, IV (OR 0.71; 95% CI 0.49-1.01; and OR 0.70; 95% CI 0.49-1.00, respectively). None of the evaluated genotypes of -2578C/A was significantly associated with the gender, age, tumor size, B symptoms and immunohistological subtype. No significant associations between the genotype of +936C/T and the clinicopathologic variables, gender, age, tumor size and B symptoms were ascertained. Both of the -2578C/A and +936C/T polymorphisms were not related to the patients' overall survival. CONCLUSION: We present the first data on VEGF gene polymorphisms in NHL. Our findings support the hypothesis that the -2578 CA and CA + AA and +936 TT VEGF genotypes and -2578A and +936T alleles are associated with decreased risk for invasion. But the investigated VEGF gene polymorphisms were not associated with prognosis in patients with NHL.
PURPOSE:Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and cancer progression. The VEGF genetic polymorphisms were shown to be independently associated with an adverse outcome in various malignancies. We investigated the possible associations of two polymorphisms (-2578C/A and +936C/T) in the VEGF gene with the clinicopathologic parameters for patients with non-Hodgkin's lymphoma (NHL). METHODS: We studied the genotype and allele frequencies of the -2578C/A and +936C/T polymorphism in DNA samples of 431 patients with NHL using restriction fragment length polymorphism typing analysis. RESULTS: The -2578A allele was significantly associated with less frequent clinical staging III, IV and bone marrow involvement (The odds ratio (OR) 0.59; 95% confidence interval (CI) 0.43-0.82; and OR 0.66; 95% CI 0.48-0.91, respectively). The CA and CA + AA genotype of the -2578C/A were significantly associated with less frequent bone marrow involvement than CC genotypes (OR 0.57; 95% CI 0.38-0.86; and OR 0.57; 95% CI 0.39-0.85, respectively). The TT genotype of the +936C/T polymorphism was significantly associated with less frequent T cell histological type, clinical staging III, IV and bone marrow involvement (OR 0.25; 95% CI 0.07-0.89; OR 0.37; 95% CI 0.15-0.89; and OR 0.31; 95% CI 0.10-0.96, respectively). The +936 T allele was marginally associated with less frequent bone marrow involvement and with Clinical staging III, IV (OR 0.71; 95% CI 0.49-1.01; and OR 0.70; 95% CI 0.49-1.00, respectively). None of the evaluated genotypes of -2578C/A was significantly associated with the gender, age, tumor size, B symptoms and immunohistological subtype. No significant associations between the genotype of +936C/T and the clinicopathologic variables, gender, age, tumor size and B symptoms were ascertained. Both of the -2578C/A and +936C/T polymorphisms were not related to the patients' overall survival. CONCLUSION: We present the first data on VEGF gene polymorphisms in NHL. Our findings support the hypothesis that the -2578 CA and CA + AA and +936 TT VEGF genotypes and -2578A and +936T alleles are associated with decreased risk for invasion. But the investigated VEGF gene polymorphisms were not associated with prognosis in patients with NHL.
Authors: Lukas A Hefler; Alexander Mustea; Dominique Könsgen; Nicole Concin; Berno Tanner; Reiner Strick; Georg Heinze; Christoph Grimm; Eva Schuster; Clemens Tempfer; Alexander Reinthaller; Robert Zeillinger Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Stephan Polterauer; Christoph Grimm; Alexander Mustea; Nicole Concin; Berno Tanner; Falk Thiel; Georg Heinze; Alexander Reinthaller; Robert Zeillinger; Lukas A Hefler Journal: Gynecol Oncol Date: 2007-02-06 Impact factor: 5.482
Authors: C Yapijakis; E Vairaktaris; S Vassiliou; A Vylliotis; E Nkenke; A M Nixon; S Derka; S Spyridonidou; E Vorris; F Neukam; E Patsouris Journal: J Cancer Res Clin Oncol Date: 2007-06-13 Impact factor: 4.553
Authors: Kristen N Ganjoo; Annette M Moore; Attilio Orazi; Joy A Sen; Cynthia S Johnson; Caroline S An Journal: J Cancer Res Clin Oncol Date: 2007-08-11 Impact factor: 4.553
Authors: Tomasz Wróbel; Grzegorz Mazur; Justyna Dzietczenia; Katarzyna Gębura; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik Journal: Biomed Res Int Date: 2013-08-26 Impact factor: 3.411
Authors: Carol Lozano-Santos; Jimena Martinez-Velasquez; Belen Fernandez-Cuevas; Natividad Polo; Belen Navarro; Isabel Millan; Jose Miguel Garcia; Rosa Collado; Pedro Sanchez-Godoy; Felix Carbonell; Jose Antonio Garcia-Vela; Jose Antonio Garcia-Marco; Natalia Gomez-Lozano Journal: PLoS One Date: 2014-06-27 Impact factor: 3.240